

# A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT06987539

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Amgen
<b>Enrollment</b>	15 participants

## Key Eligibility Criteria

---

### Inclusion (17)

- Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
- Age e 2 to < 18 years of age on the day of enrollment.
- Diagnosis of gMG defined as:
- Positive serologic test for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody (Ab) titers as confirmed at screening (1 retest allowed), and
- At least 1 of the following:  
... and 12 more (see full listing online)

### Exclusion (14)

- Employees of the Sponsor, contract research organization (CRO), site staff, and their family members.
- Thymectomy within 12 months prior to baseline (Day 1) visit or planned thymectomy during the duration of the treatment period.
- Unresected thymoma- Participants with benign thymoma resected > 12 months prior to screening may enroll.
- History of recurrent significant infections.
- Known immunodeficiency disorder, including current infection or positive test for human immunodeficiency virus (HIV).  
... and 9 more (see full listing online)

## Locations (1 total)

---

Austin Neuromuscular Center, Austin, Texas, United States